IBANDRONATE SODIUM ANHYDROUS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H22NO7P2.Na
Molecular Weight	341.2108
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of IBANDRONATE SODIUM ANHYDROUS

Structure Search

SMILES

[Na+].CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)([O-])=O

InChI

InChIKey=LXLBEOAZMZAZND-UHFFFAOYSA-M

InChI=1S/C9H23NO7P2.Na/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	C9H22NO7P2
Molecular Weight	318.221
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/dosage/ibandronate.html

Ibandronic acid (INN) or ibandronate sodium (USAN) is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug. Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers. In 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint and/or muscle pain.[4] A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. Ibandronic acid is marketed under the trade names Boniva in the USA, Bondronat in Europe, Bonviva in Asia, Ibandrix in Ecuador and Bondrova in Bangladesh.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mevalonate Pathway 3 Target ID: WP3104 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16620148	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Postmenopausal osteoporosis 59 Sources: https://clinicaltrials.gov/ct2/show/NCT02604836	Primary	Approved 8583	Boniva Approved Use Unknown
Osteoporosis 101 Sources: https://www.drugs.com/cdi/ibandronate.html	Primary	Approved 8583	Boniva Approved Use Unknown
Bone cancer 3 Sources: https://clinicaltrials.gov/ct2/show/NCT02561039	Primary	Approved 8583	Boniva Approved Use Directions: Acne Clearing Cleanser Acne Clearing Tonic Acne Clearing Treatment 101

C_max

Value	Dose	Co-administered	Analyte	Population
90.64 ng/mL EXPERIMENT https://synapse.koreamed.org/Synapse/Data/PDFData/1179TCP/tcp-22-22.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		IBANDRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
549.24 ng × h/mL EXPERIMENT https://synapse.koreamed.org/Synapse/Data/PDFData/1179TCP/tcp-22-22.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		IBANDRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
32.38 h EXPERIMENT https://synapse.koreamed.org/Synapse/Data/PDFData/1179TCP/tcp-22-22.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		IBANDRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg 1 times / month multiple, oral Dose: 100 mg, 1 times / month Route: oral Route: multiple Dose: 100 mg, 1 times / month Sources: https://pubmed.ncbi.nlm.nih.gov/28389932	unhealthy, 55–74 years Health Status: unhealthy Age Group: 55–74 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/28389932	Sources: https://pubmed.ncbi.nlm.nih.gov/28389932
2.5 mg 1 times / day multiple, oral Recommended Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf	Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (NOS) (4%) Musculoskeletal disorder NOS (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
2 mg 1 times / 2 months multiple, intravenous Dose: 2 mg, 1 times / 2 months Route: intravenous Route: multiple Dose: 2 mg, 1 times / 2 months Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf	Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (NOS) (4%) Musculoskeletal disorder NOS (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
3 mg 1 times / 3 months multiple, intravenous Dose: 3 mg, 1 times / 3 months Route: intravenous Route: multiple Dose: 3 mg, 1 times / 3 months Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf	Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (NOS) (4%) Musculoskeletal disorder NOS (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: https://clinicaltrials.gov/ct2/show/NCT00545051	unhealthy Health Status: unhealthy Sex: F Sources: https://clinicaltrials.gov/ct2/show/NCT00545051	Other AEs: Agranulocytosis, Acute pancreatitis... Other AEs: Agranulocytosis (serious, 1 patient) Acute pancreatitis (serious, 1 patient) Acute pyelonephritis (serious, 1 patient) Sepsis (serious, 1 patient) Concussion (serious, 1 patient) Poisoning (serious, 1 patient) Follicle centre lymphoma diffuse small cell lymphoma (serious, 1 patient) Malignant tongue neoplasm (serious, 1 patient) Transient ischaemic attack (serious, 1 patient) Pulmonary embolism (serious, 1 patient) Deep vein thrombosis (serious, 2 patients) Influenza (below serious, 4 patients) Arthralgia (below serious, 8 patients) Rheumatoid arthritis (below serious, 4 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00545051
150 mg 1 times / month multiple, oral Dose: 150 mg, 1 times / month Route: oral Route: multiple Dose: 150 mg, 1 times / month Sources: https://clinicaltrials.gov/ct2/show/NCT00397839	unhealthy Health Status: unhealthy Sex: M Sources: https://clinicaltrials.gov/ct2/show/NCT00397839	Other AEs: Death, Syncope... Other AEs: Death (serious, 1 patient) Syncope (serious, 2 patients) Pneumonia (serious, 1 patient) Retinal detachment (serious, 1 patient) Rectal haemorrhage (serious, 1 patient) Pneumoconiosis (serious, 1 patient) Nasopharyngitis (below serious, 7 patients) Nausea (below serious, 4 patients) Upper respiratory tract infection (below serious, 3 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00397839

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 substrate 1946	inhibitor 2438 substrate 1193	inhibitor 2507 substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060	CYP1A2 1197 CYP2A6 626 CYP2C19 1119 CYP2E1 729

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0	no
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=5 Page: 5.0	no

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0	no
CYP2A6 626	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0	no
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0	no
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0	no
CYP2E1 729	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0	no
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_biopharmr.pdf#page=11 Page: 11.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-455_Boniva_pharmr_P1.pdf#page=4 Page: 4.0

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-1493	http://www.3bsc.com/index/pro_info.php?id=55209
AA Blocks	AA000AF6	http://www.aablocks.com/goods/Goods/detail?id=AA000AF6
abcr GmbH	AB506647	http://www.abcr.com/shop/en/AB506647
Acadechem	ACDS-026262	http://www.acadechemical.com/product/100961
Achemtek	0104-008135	http://www.achemtek.com/114084-78-5
AEchem Scientific Corp., USA	AE032312	http://www.aechemsc.com/info_products/AE032312.php
AHH Chemical co.,ltd	MT-01142	http://www.ahhchemical.com/product/MT-01142.html
AK Scientific, Inc. (AKSCI)	71724	http://www.aksci.com/item_detail.php?cat=71724
Angene	AGN-PC-04XVIP	http://www.angenechemical.com/productshow/AGN-PC-04XVIP.html
Aurora Fine Chemicals LLC	A13.112.890	http://online.aurorafinechemicals.com/info?ID=A13.112.890
Aurum Pharmatech LLC	M-1207	http://www.Aurumpharmatech.com/Product/ProductDetails/M_1207
AvaChem Scientific	2445A	http://www.avachem.com/productSearch.asp?2445A
BioChemPartner	BCP13798	http://www.biochempartner.com/114084-78-5-BCP13798
BioSynth	J-003052	https://www.biosynth.com/en/products/all-products/products/J-003052.html
BLD Pharm	BD17613	http://www.bldpharm.com/products/114084-78-5.html
Boerchem	BC219057	http://www.boerchem.com/?product_36883.html
Chem Scene	CS-2726	http://www.chemscene.com/114084-78-5.html
ChemMol	30108986	http://www.chemmol.com/chemmol/30108986.html
ChemMol	44005823	http://www.chemmol.com/chemmol/44005823.html
ChemMol	49409545	http://www.chemmol.com/chemmol/49409545.html
ChemMol	81411772	http://www.chemmol.com/chemmol/81411772.html
Chemspace	CSSB00000036762	https://chem-space.com/CSSB00000036762
Clearsynth	CS-BU-00048	https://www.clearsynth.com/en/CSBU00048.html
Clearsynth	CS-O-01646	http://www.clearsynth.com/en/CSO01646.html
Clearsynth	CS-O-30604	https://www.clearsynth.com/en/CSO30604.html
CSNpharm	CSN12493	https://www.csnpharm.com/products/ibandronate.html
Finetech	FT-0602640	http://www.finetechnology-ind.com/prod/detail/pub/114084-78-5.html
Finetech	FT-0670253	http://www.finetechnology-ind.com/prod/detail/pub/1130899-41-0.html
Hefei Hirisun Pharmatech Co., Ltd	HR130939	http://hirisunpharm.com/114084-78-5.html
iChemical	EBD38131	http://www.ichemical.com/chemicals/cas-114084-78-5
Matrix Scientific	100579	https://www.matrixscientific.com/100579.html
MedChem Express	HY-B0515A	https://www.medchemexpress.com/Ibandronic-acid.html
MuseChem	I000530	https://www.musechem.com/product/I000530.html
OChem	7534	http://www.ocheminc.com/index.php?act=psearch&pid=084I785
Sinfoo Biotech	S010605	http://www.sinfoobiotech.com/product/1014003
Smolecule	S594667	https://www.smolecule.com/products/s594667
THE BioTek	bt-300824	https://www.thebiotek.com/product/others/bt-300824
Yuhao Chemical	RT16287	http://www.chemyuhao.com/114084-78-5.html

PubMed

Title	Date	PubMed
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.	2004-10	15071723
Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.	2004-05	15068492
Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells.	2004-05	15067347
Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats.	2004-05	14741628
Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.	2004-04	15041119
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.	2004-03-22	15026791
Nephrotoxicity of third-generation, intravenous bisphosphonates.	2004-03-01	15036766
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.	2004-03	14998861
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.	2004-03	14727011
[Ibandronate].	2004-02	15035186
Effect of augmentation cystoplasty on bone metabolism in chronic uremic rats.	2004-02	14713854
Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat.	2004-01-16	14578360
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.	2004-01	14753731
Hypercalcemia of malignancy.	2004-01	14730509
[How to treat tumor-induced hypercalcemia].	2003-12-15	15008469
Bone resorption predicts for skeletal complications in metastatic bone disease.	2003-12-01	14647134
Is ibandronate effective in multiple myeloma?	2003-12	14703700
[Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].	2003-12	14685711
Injectable drug dampens bone loss.	2003-12	14679970
Bisphosphonates in children with bone diseases.	2003-11-20	14631923
Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth.	2003-11-10	14506749
Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples.	2003-11-03	14583776
Ibandronate: new options in the treatment of osteoporosis.	2003-11	14702133
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.	2003-10	14610641
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.	2003-10	14557430
The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status.	2003-10	14555263
Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.	2003-10	12972476
The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats.	2003-09-30	12965119
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.	2003-09	12954579
Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years.	2003-08	14669826
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.	2003-08	14661816
Oral weekly ibandronate prevents bone loss in postmenopausal women.	2003-08	12859697
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.	2003-08	12783289
The bisphosphonate ibandronate stimulates reverse cholesterol transport out of monocytoid cells by enhanced ABCA1 transcription.	2003-07-18	12849976
Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.	2003-07-07	12838321
Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate.	2003-07	12830369
Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate.	2003-06-15	12810621
Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis.	2003-06	12846348
Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens.	2003-06	12810176
Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.	2003-06	12730532
Effects of ibandronate on inflammation in mouse antigen-induced arthritis.	2003-05	12813627
Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.	2003-04-22	12698202
Collagen crosslink excretion and staging of oral cancer.	2003-04-07	12671712
The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.	2003-04	12689686
Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate.	2003-03-15	12641503
New insights into the molecular mechanisms of action of bisphosphonates.	2003	14529538
[Effects of ibandronate on the osteopenia process in tail-suspended rats].	2003	14503187
Bisphosphonates in the management of metastatic prostate cancer.	2003	12949427
Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.	2003	12818000
Drugs in development: bisphosphonates and metalloproteinase inhibitors.	2003	12716443

Patents

Sample Use Guides

In Vivo Use Guide

Oral: 150 mg orally once a month on the same day each month IV Injection: 3 mg by IV injection over 15 to 30 seconds every three months.

Route of Administration: Other

In Vitro Use Guide

Cells were cultivated in cell culture flasks at 37_Cand5%CO2. The culture media were as recommended by the American Type Culture Collection (ATCC) for MDA-MB-231 breast cancer DMEM (Sigma-Aldrich, St. Louis, MO, USA), which contained 10% fetal calf serum (FCS); PC-3 prostate carcinoma DMEM-F12 (Sigma-Aldrich) with 10% FCS. MG-63 and U2-OS osteosarcoma were cultured in AlphaMEM (Biochrom, Berlin, Germany) medium containing 10% FBS. For the HMC1.1 cell line, we used Iscove’s Modified Dulbecco’s Medium (IMDM; Thermo Fisher Scientific, Waltham, MA) supplemented with 260 nM thioglycerol (Sigma-Aldrich) and20%fetal bovine serum (FBS). All culture media contained 10 mg/mL gentamycin (Sigma-Aldrich). To guarantee optimal growth, cells were split two times a week and reseeded at a density of 2-5 x 105 cells/mL. One day after splitting, 32 mMsimvastatin (Sigma-Aldrich) or 150 mM ibandronate (Sigma-Aldrich) were added to the culture medium for 72 hours. This is the dose that attenuated cell proliferation with a half maximal effect. NADP/NADPH analyses were performed directly in 96-well culture plates after 24 or 48 hours

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:26:13 GMT 2025` Edited by `admin` on `Mon Mar 31 21:26:13 GMT 2025`
Record UNII	23Y0B94E49
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BONDRONAT

Preferred Name

English

IBANDRONATE SODIUM ANHYDROUS

Common Name

English

Ibandronate sodium [WHO-DD]

Common Name

English

BONVIVA

Brand Name

English

SODIUM IBANDRONATE ANHYDROUS

Common Name

English

PHOSPHONIC ACID, (1-HYDROXY-3-(METHYLPENTYLAMINO)PROPYLIDENE)BIS-, MONOSODIUM SALT

Common Name

English

IBANDRONIC ACID SODIUM SALT [MI]

Common Name

English

SODIUM IBANDRONATE

Common Name

English

Code System Code Type Description

CAS

138844-81-2